生物制剂时代IBD非择期手术的术后死亡率
该研究基于纽约州2000至2013年数据,分析炎症性肠病(IBD)非择期手术比例及30天死亡率趋势。结果显示溃疡性结肠炎(UC)非择期手术死亡率从10.2%升至15%,克罗恩病(CD)从3.3%降至2.2%;2007至2013年UC非择期手术与30天死亡风险增加82%相关(OR 1.82,CI 1.19-2.62)。
要点
- UC非择期手术30天死亡率近年翻倍,需重新评估临床决策与照护路径。
- CD非择期手术死亡率下降,但UC与CD均存在医院间23倍死亡率差异。
- 生物制剂时代IBD非择期手术比例稳定,但UC术后死亡风险显著增加。
核心结论
- 尽管IBD非择期手术率稳定,但UC患者非择期手术后30天死亡率近年翻倍。
- 需进一步评估临床决策和照护路径以改善高危人群结局。
研究设计与样本
- 回顾性队列研究,查询纽约州2000至2013年住院数据,纳入15,837例肠道切除(UC 5,297例;CD 10,540例)。
- 采用混合效应分析评估患者、外科医生和医院层面因素及医院间变异与30天死亡率的关系。
主要发现
- 2000-2006至2007-2013年,UC非计划入院增加50%,CD增加41%,但非择期手术比例无变化(UC 38% vs 38%;CD 45% vs 42%)。
- 非择期手术死亡率:UC从10.2%升至15%,CD从3.3%降至2.2%。
- 2007-2013年UC非择期手术与30天死亡风险增加82%相关(OR 1.82;CI 1.19-2.62)。
- 控制患者因素后,UC和CD的医院间死亡率差异达23倍。
临床怎么用
- 对UC非择期手术患者应加强围术期风险评估与照护路径优化。
- 关注医院间死亡率巨大差异,推动诊疗同质化。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The aim of the study was to analyze recent trends in the rate of nonelective surgery and corresponding mortality for inflammatory bowel disease (IBD) patients since the rise of biologic use. BACKGROUND: Modern biologic therapy has improved outcomes for IBD, but little is known about the impact on mortality rates after nonelective surgery. METHODS: New York's Statewide Planning & Research Cooperative System was queried for hospital admissions for ulcerative colitis (UC) with concurrent colectomy and Crohn disease (CD) with concurrent small bowel resection or colectomy from 2000 to 2013. Mixed-effects analyses assessed patient, surgeon, and hospital-level factors and hospital-level variation associated with 30-day mortality after nonelective surgery. RESULTS: Between 2000 to 2006 and 2007 to 2013, the number of unscheduled IBD-related admissions increased by 50% for UC and 41% for CD, but no change in the proportion of nonelective surgery cases was observed (UC=38% vs 38%; CD=45% vs 42%) among 15,837 intestinal resections (UC=5,297; CD=10,540). Nonelective surgery mortality rates between 2000 to 2006 and 2007 to 2013 were high and increased for UC (10.2% vs 15%) but decreased for CD (3.3% vs 2.2%). Nonelective surgery in 2007 to 2013 was associated with an 82% increased risk of 30-day mortality in UC cases (odds ratio: 1.82; confidence interval: 1.19-2.62). After controlling for patient-level factors, large hospital-level variation was observed with 23-fold difference in mortality for both UC and CD. CONCLUSIONS: Although nonelective IBD surgery rates have remained stable, associated 30-day mortality for UC has doubled in recent years despite advances in medical management. Current clinical decision-making and care pathways must be further evaluated to improve outcomes in this high-risk population.
引用
- Justiniano CF, Aquina CT, Becerra AZ, et al. Postoperative Mortality After Nonelective Surgery for Inflammatory Bowel Disease Patients in the Era of Biologics. Ann Surg. 2019. PMID: 29232213. doi:10.1097/SLA.0000000000002628
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。